Frontlight ResearchEarly access
Taking people in South KoreaPhase 1
Tests ERAS-0015 alone or combined in advanced solid tumors
Tests whether ERAS-0015 is safe in adults with advanced solid tumors.
Key facts
- Who runs it
- Erasca, Inc.
- Where
- Haeundae and Seoul, South KoreaSee the 2 sitesAlso in 2 other countries, 12 sites
- Trial code
- Registry title
- A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 600 people, planned
- Started
- 5 Jun 2025
- Expected to end
- 1 Dec 2028
- Type of study
- Interventional, 2 groups
- Treatments tested
- ERAS-0015
- ERAS-0015 in combination
- Record updated
- 16 November 2026
Who can take part
- Age
- 18 years to 99 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 15 criteriaShow less
Who can take part
- Age ≥ 18 years
- Willing and able to give written informed consent
- Pathological documentation of tumor type and mutation prior to the first dose of study drug(s), for applicable cohorts
- There is no available standard systemic therapy available for the patient's tumor histology and/or molecular biomarker profile; or standard therapy is intolerable, not effective, or not accessible; or patient has refused standard therapy. Does not apply to newly diagnosed Pancreatic Ductal Carcinoma (PDAC) cohort
- Able to swallow oral medication
- Have Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1
- Adequate cardiovascular, hematological, liver, and renal function
- Willing to comply with all protocol-required visits, assessments, and procedures
Who cannot take part
- Previous treatment with a RAS inhibitor
- Is currently receiving another study therapy or has participated in a study of an investigational agent and received study therapy within 4 weeks of the first dose of ERAS-0015
- Received prior palliative radiation within 14 days of Cycle 1, Day 1
- Prior surgery (e.g., gastric bypass surgery, gastrectomy) or gastrointestinal dysfunction (e.g., Crohn's disease, ulcerative colitis, short gut syndrome) that may affect drug absorption
- Have any underlying medical condition, psychiatric condition, or social situation that, in the opinion of the Investigator, would compromise study administration as per protocol or compromise the assessment of AEs
- Have primary central nervous system (CNS) tumors
- Are pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the trial
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 99 years old?
Where in South Korea
Also in 2 other countries, 12 sites
- Inje University Haeundae Paik Hospital Clinical Trial CenterHaeundae, South KoreaContact: Erasca Clinical Team TeamTaking people
- Seoul St. Mary's Hospital Clinical Trial CenterSeoul, South KoreaContact: Erasca Clinical Team TeamTaking people
About the trial
What the trial wants to find out
The main purpose of the study is to assess whether the study drug, ERAS-0015, is safe and tolerable when administered to patients with advanced or metastatic solid tumors with certain RAS mutations. ERAS-0015 will be given alone or in combination with other treatments.
The 2 groups in the trial
- ERAS-0015 Monotherapy Dose Optimization.Treatment being tested
Escalating doses of ERAS-0015 administered orally.
Treatment: ERAS-0015
- ERAS-0015 Combination Dose OptimizationTreatment being tested
ERAS-0015 administered orally with another investigational agent.
Treatment: ERAS-0015 in combination
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- A Phase 1/2 Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of ERAS-0015 Monotherapy and in Combination in Patients Advanced Solid Tumors
- Plain-language title
- Tests ERAS-0015 alone or combined in advanced solid tumorsGenerated from the registry record. The registry title is the official one.
- Fit questions
- Built from NCT06983743, who can take part
- Record updated
- 16 November 2026